Atomoxetine for the treatment of executive dysfunction in Parkinson's disease: A pilot open-label study

Laura Marsh, Kevin Biglan, Melissa Gerstenhaber, James R. Williams

Research output: Contribution to journalArticle

Abstract

Executive dysfunction (ED) is a prominent and often disabling feature of cognitive impairment in Parkinson's disease (PD). Few studies have examined treatments. Given the role of noradrenergic pathology in ED, atomoxetine, a norepinephrine reuptake inhibitor indicated for attention deficit hyperactivity disorder (ADHD), may be a potential treatment for PD-related ED. Twelve patients with PD and disabling ED completed an 8-week pilot open-label, flexible dose (25-100 mg/day) trial of atomoxetine. On primary outcome measures, atomoxetine was associated with improved ED based on the Clinical Global Impression-Change Scale (75% positive response rate; 95% CI: 43-95%, P <05) and behavioral measures of ED [Frontal Systems Behavior Scale (FrSBE) Executive Dysfunction and Connors Adult ADHD Rating Scale (CAARS) inattention/ memory subscales]. Adverse effects included sleep and gastrointestinal disturbances and hypomania. Atomoxetine is tolerable in PD and may benefit clinical manifestations of ED, warranting further study in controlled trials.

Original languageEnglish (US)
Pages (from-to)277-282
Number of pages6
JournalMovement disorders : official journal of the Movement Disorder Society
Volume24
Issue number2
DOIs
StatePublished - Jan 30 2009

Fingerprint

Parkinson Disease
Attention Deficit Disorder with Hyperactivity
Therapeutics
Norepinephrine
Sleep
Outcome Assessment (Health Care)
Pathology
Atomoxetine Hydrochloride

Keywords

  • Atomoxetine
  • Cognition
  • Executive dysfunction
  • Norepinephrine reuptake inhibition
  • Parkinson's disease

ASJC Scopus subject areas

  • Clinical Neurology
  • Neurology

Cite this

Atomoxetine for the treatment of executive dysfunction in Parkinson's disease : A pilot open-label study. / Marsh, Laura; Biglan, Kevin; Gerstenhaber, Melissa; Williams, James R.

In: Movement disorders : official journal of the Movement Disorder Society, Vol. 24, No. 2, 30.01.2009, p. 277-282.

Research output: Contribution to journalArticle

Marsh, Laura ; Biglan, Kevin ; Gerstenhaber, Melissa ; Williams, James R. / Atomoxetine for the treatment of executive dysfunction in Parkinson's disease : A pilot open-label study. In: Movement disorders : official journal of the Movement Disorder Society. 2009 ; Vol. 24, No. 2. pp. 277-282.
@article{17a133c8bd2e4c40ae61b1d294705d37,
title = "Atomoxetine for the treatment of executive dysfunction in Parkinson's disease: A pilot open-label study",
abstract = "Executive dysfunction (ED) is a prominent and often disabling feature of cognitive impairment in Parkinson's disease (PD). Few studies have examined treatments. Given the role of noradrenergic pathology in ED, atomoxetine, a norepinephrine reuptake inhibitor indicated for attention deficit hyperactivity disorder (ADHD), may be a potential treatment for PD-related ED. Twelve patients with PD and disabling ED completed an 8-week pilot open-label, flexible dose (25-100 mg/day) trial of atomoxetine. On primary outcome measures, atomoxetine was associated with improved ED based on the Clinical Global Impression-Change Scale (75{\%} positive response rate; 95{\%} CI: 43-95{\%}, P <05) and behavioral measures of ED [Frontal Systems Behavior Scale (FrSBE) Executive Dysfunction and Connors Adult ADHD Rating Scale (CAARS) inattention/ memory subscales]. Adverse effects included sleep and gastrointestinal disturbances and hypomania. Atomoxetine is tolerable in PD and may benefit clinical manifestations of ED, warranting further study in controlled trials.",
keywords = "Atomoxetine, Cognition, Executive dysfunction, Norepinephrine reuptake inhibition, Parkinson's disease",
author = "Laura Marsh and Kevin Biglan and Melissa Gerstenhaber and Williams, {James R.}",
year = "2009",
month = "1",
day = "30",
doi = "10.1002/mds.22307",
language = "English (US)",
volume = "24",
pages = "277--282",
journal = "Movement Disorders",
issn = "0885-3185",
publisher = "John Wiley and Sons Inc.",
number = "2",

}

TY - JOUR

T1 - Atomoxetine for the treatment of executive dysfunction in Parkinson's disease

T2 - A pilot open-label study

AU - Marsh, Laura

AU - Biglan, Kevin

AU - Gerstenhaber, Melissa

AU - Williams, James R.

PY - 2009/1/30

Y1 - 2009/1/30

N2 - Executive dysfunction (ED) is a prominent and often disabling feature of cognitive impairment in Parkinson's disease (PD). Few studies have examined treatments. Given the role of noradrenergic pathology in ED, atomoxetine, a norepinephrine reuptake inhibitor indicated for attention deficit hyperactivity disorder (ADHD), may be a potential treatment for PD-related ED. Twelve patients with PD and disabling ED completed an 8-week pilot open-label, flexible dose (25-100 mg/day) trial of atomoxetine. On primary outcome measures, atomoxetine was associated with improved ED based on the Clinical Global Impression-Change Scale (75% positive response rate; 95% CI: 43-95%, P <05) and behavioral measures of ED [Frontal Systems Behavior Scale (FrSBE) Executive Dysfunction and Connors Adult ADHD Rating Scale (CAARS) inattention/ memory subscales]. Adverse effects included sleep and gastrointestinal disturbances and hypomania. Atomoxetine is tolerable in PD and may benefit clinical manifestations of ED, warranting further study in controlled trials.

AB - Executive dysfunction (ED) is a prominent and often disabling feature of cognitive impairment in Parkinson's disease (PD). Few studies have examined treatments. Given the role of noradrenergic pathology in ED, atomoxetine, a norepinephrine reuptake inhibitor indicated for attention deficit hyperactivity disorder (ADHD), may be a potential treatment for PD-related ED. Twelve patients with PD and disabling ED completed an 8-week pilot open-label, flexible dose (25-100 mg/day) trial of atomoxetine. On primary outcome measures, atomoxetine was associated with improved ED based on the Clinical Global Impression-Change Scale (75% positive response rate; 95% CI: 43-95%, P <05) and behavioral measures of ED [Frontal Systems Behavior Scale (FrSBE) Executive Dysfunction and Connors Adult ADHD Rating Scale (CAARS) inattention/ memory subscales]. Adverse effects included sleep and gastrointestinal disturbances and hypomania. Atomoxetine is tolerable in PD and may benefit clinical manifestations of ED, warranting further study in controlled trials.

KW - Atomoxetine

KW - Cognition

KW - Executive dysfunction

KW - Norepinephrine reuptake inhibition

KW - Parkinson's disease

UR - http://www.scopus.com/inward/record.url?scp=61649118193&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=61649118193&partnerID=8YFLogxK

U2 - 10.1002/mds.22307

DO - 10.1002/mds.22307

M3 - Article

C2 - 19025777

AN - SCOPUS:61649118193

VL - 24

SP - 277

EP - 282

JO - Movement Disorders

JF - Movement Disorders

SN - 0885-3185

IS - 2

ER -